Neurocrine/Takeda's Luvadaxistat Fails To Improve Schizophrenia Symptom Severity

Neurocrine Biosciences Inc (NASDAQ: NBIX) announces topline data from Phase 2 INTERACT study evaluating luvadaxistat (NBI-1065844/TAK-831) for the treatment of negative symptoms and cognitive impairment associated with schizophrenia.

• Luvadaxistat is an oral, selective inhibitor with a high binding affinity to d-amino acid oxidase. It targets glutamate, an abundant neurotransmitter in the brain. 
• The trial did not meet its primary endpoint as measured by the change from baseline on the PANSS NSFS (score used to assess schizophrenia symptom severity) at Day 84.
• Luvadaxistat met secondary endpoints of cognitive assessment.
• Takeda Pharmaceutical Co Ltd (NYSE: TAK) granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including luvadaxistat, in June last year.
• The results from the study are being evaluated to determine the next steps for development activities.
• Price Action: TAK shares are up 1.88% at $17.30, while NBIX shares are down by 5.03% at $103.93 in the pre-market session on the last check Tuesday.